Geron Executive Compensation (FY25)
GERN · Executive and director compensation, fiscal 2025 only
The Geron brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): May 27, 2026
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
157 figures on this page: 147 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Geron's chief executive and what were they paid?
Harout Semerjian, President and Chief Executive Officer, received $10,221,755 in total compensation for fiscal 2025.
What was Geron's say-on-pay result?
Shareholders supported the say-on-pay proposal with 94.6% of votes cast including abstentions in favor at the meeting held May 20, 2026 for fiscal 2025.
Which companies are in Geron's peer group?
The disclosed peer group includes Axsome Therapeutics, Coherus Oncology, Inc., Dynavax Technologies, Madrigal Pharmaceuticals and Revance Therapeutics, Inc., among others.
What is Geron's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 35:1, against median employee compensation of $314,826.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Harout Semerjian President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
John Scarlett Former Chairman of the Board, President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Andrew Grethlein Former Executive Vice President, Chief Operating Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Ahmed ElNawawi Executive Vice President, Chief Commercial Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
James Ziegler Former Executive Vice President, Chief Commercial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Michelle Robertson Executive Vice President, Chief Financial Officer, Treasurer and Interim Secretary Served on an interim basis | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Joseph Eid Executive Vice President, Research and Development, Chief Medical Officer | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Dawn Bir Former Interim President and Chief Executive Officer Departed during or after this year Served on an interim basis | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Ahmed ElNawawi | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrew J. Grethlein | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrew J. Grethlein | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew J. Grethlein | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Dawn C. Bir | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Harout Semerjian | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| James Ziegler | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| James Ziegler | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John A. Scarlett | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John A. Scarlett | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michelle J. Robertson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michelle J. Robertson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Andrew Grethlein | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Joseph Eid | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| John Scarlett | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Michelle Robertson | Option | ◇ | — | ◇ | — |
| Dawn Bir | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Axsome Therapeutics AXSM
- Coherus Oncology, Inc. CHRS
- Dynavax Technologies DVAX
- Madrigal Pharmaceuticals MDGL
- Revance Therapeutics, Inc. RVNC
- Seres Therapeutics, Inc. MCRB
- Syndax Pharmaceuticals SNDX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 20, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 21, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 9, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 31, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 10, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 11, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 5, 2020 | = | ◇ | ◇ | ◇ |
| 2017 | May 15, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 9, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | May 17, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Geron disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Geron sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
157 figures on this page: 147 cited to the filing that reported them, 10 calculated from figures it prints.
147 cited to the filing
10 calculated from the filing
Documents cited
- 0001193125-26-241842
- 0000886744-26-000024CEO Pay Ratio · Executive Compensation Tables and Related Narrative Disclosure · Grants of Plan-Based Awards · Non-Employee Director Role · and 2 more sections
- 0000886744-25-000032
- 0000950170-24-058622
- 0000950170-23-026166Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001206774-22-001399Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001206774-21-001453Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001206774-20-001800Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001206774-18-001662Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001206774-17-001597Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001206774-16-005987
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Geron executive compensation, FY2025.” https://intel.velarion.ai/comp/GERN (accessed 2026).
Short form: data: Velarion
The Geron brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Geron and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Geron discloses
The companies named in GERN's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}